ReviewRelapsing polychondritis: An autoimmune disease with many faces
Introduction
Relapsing polychondritis (RPC) is a rare immune mediated disease of unknown aetiology which is associated with inflammation in cartilaginous, especially hyaline cartilage, tissue throughout the body. Most prominent manifestation is the inflammation of hyaline cartilage of the ear [1]. Around 30% of these cases are associated with other diseases especially systemic vasculitis or myelodysplastic syndrome.
The epidemiology of RPC remains unknown and the incidence is estimated to be 3 per million population with an onset around 40–60 years [2].
The systemic occurrence and often aggressive course of RPC necessitate an immunosuppressant therapy. Glucocorticosteroids, cyclophosphamide or anti-tumor necrosis factor alpha blockers (TNF-alpha antagonists) are used for the treatment of RPC with varying efficacy.
This review points out the clinical manifestation, pathology and therapy of the rare disease of RPC.
Section snippets
Epidemiology and genetic association
The epidemiology of RPC in detail still remains unknown. RPC appears among all individuals of all races and age groups without gender domination [3]. Onset seems most likely between the ages of 40–60, but there are some reports that RPC can occur in childhood [2]. As far as it is still known RPC is not a family disease, although examinations indicate a possible genetic contribution. Gimovsky and Nishiyama [4] reported the only case suggesting the possibility of placental transmission.
Genetic
Pathogenesis
Hypothetically the pathogenesis of RPC begins with an insult that induces the exposure of connective tissue or cell membrane epitopes, which can lead to an inflammatory and genetically conditioned immune response [9].
This insult can be caused by nutrient vasculature damage, trauma, toxic, chemical or infectious agents and also antigenic mimicry between an infectious agent and a given connective tissue antigen [10].
Potentially inflammatory cell exudates, which are responsible for tissue injury,
Clinical manifestations
Clinical manifestation of RPC varies in severity and duration. Auricular involvement is the most common feature, and also all other organs with (hyaline) cartilage structures could be involved including for example the costal cartilage, eyes, airways and many more as described below [1] (Table 1).
Diagnosis
Diagnosis of RPC is a combination of clinical findings, supportive laboratory parameters, imaging, and biopsy of involved cartilaginous tissues.
There were some trials to define criteria for RPC. Established diagnostic criteria are the original so called McAdam's criteria that require the presence of three or more of the following clinical features [1].
Bilateral auricular chondritis; nonerosive, seronegative inflammatory polyarthritis; nasal chondritis; ocular inflammation; respiratory tract
Treatment of relapsing polychondritis
The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of different therapies. Decisions about therapy of RPC in current use are largely empiric and based on case reports but also on pathophysiological considerations.
The type of medical therapy given varies with the clinical estimate of disease activity and severity.
Conclusion
RPC is a challenging disease because the symptoms are often disguised and many differential diagnoses are possible. So it needs interdisciplinary affords to diagnose and treat RPC.
Varying possibilities in treatment from “classic” immunosuppressive agents to new approaches like the TNF-alpha antagonists and also the supportive management of accompanying problems should be considered.
Take-home messages
- •
Relapsing polychondritis (RPC) is an inflammation of hyaline cartilage throughout the body that affects typical at first the ear cartilage.
- •
Studies revealed genetic association of RPC to different HLA types, especially to HLA-DR4.
- •
Approximately 30% with RPC present a coexisting form of systemic vasculitis, connective tissue disease, autoimmune or malignant disorders.
- •
Pleomorphic perichondrial infiltrate with a variable proportion of polymorphonuclear cells, monocytes, macrophages with expressing
References (61)
- et al.
Gender as risk factor for autoimmune diseases
J Autoimmun
(2007) - et al.
Relapsing polychondritis in pregnancy: a case report and review
Am J Obstet Gynecol
(1989) - et al.
The genetics and epigenetics of autoimmune diseases
J Autoimmun
(2009) - et al.
Ocular and systemic findings in relapsing polychondritis
Ophthalmology
(1986) - et al.
Airway complications in relapsing polychondritis
Ann Thorac Surg
(1991) - et al.
Use of glucocorticoids and risk of infections
Autoimmun Rev
(2008) - et al.
Biological and clinical effects of anti-TNFα treatment
Autoimmun Rev
(2007) - et al.
Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned?
J Autoimmun
(2008) - et al.
Treatment of diffuse tracheomalacia secondary to relapsing polychondritis with continuous positive airway pressure
Chest
(1997) - et al.
Cardiovascular involvement in relapsing polychondritis
Semin Arthritis Rheum
(1997)